NHS launches groundbreaking sickle cell gene therapy
By Lee Peart 31 January 2025
A groundbreaking gene editing treatment is being offered to patients with sickle cell disease from today.
Practice Development Lead
PO5 - £52,194 to £55,323
Greenwich, London (Greater)PO5 - £52,194 to £55,323
Senior Home Support Assistant
Band D, SCP 9 -17 (£27,254- £31,022 per annum), pro rata
Sandwell, West MidlandsBand D, SCP 9 -17 (£27,254- £31,022 per annum), pro rata
Welfare Rights Team Lead
Band G SCP 32-37 (£42,839 - £48,226 per annum)
Sandwell, West MidlandsBand G SCP 32-37 (£42,839 - £48,226 per annum)
Practice Development Lead
PO5 - £52,194 to £55,323
Greenwich, London (Greater)PO5 - £52,194 to £55,323
Senior Home Support Assistant
Band D, SCP 9 -17 (£27,254- £31,022 per annum), pro rata
Sandwell, West MidlandsBand D, SCP 9 -17 (£27,254- £31,022 per annum), pro rata
Welfare Rights Team Lead
Band G SCP 32-37 (£42,839 - £48,226 per annum)
Sandwell, West MidlandsBand G SCP 32-37 (£42,839 - £48,226 per annum)
©2024 Hemming Group Limited. Registered in England and Wales. Registered No: 490200. VAT number GB342 023 408
